1-6 of 6
Marcy Vallone
Close
Sort by
Journal Articles

Results of PX-171-003-A1, An Open-Label, Single-Arm, Phase 2 (Ph 2) Study of Carfilzomib (CFZ) In Patients (pts) with Relapsed and Refractory Multiple Myeloma (MM)

David Samuel diCapua Siegel, MD, PhD, Thomas Martin, MD, Michael Wang, MD, Ravi Vij, MBBS, MD, Andrzej J Jakubowiak, MD, PhD, Sundar Jagannath, MD, Sagar Lonial, MD, Vishal Kukreti, MD, FRCPC, Nizar J Bahlis, MD, Melissa Alsina, MD, Asher A. Chanan-Khan, George Somlo, MD, Francis Buadi, MD, Frederic J. Reu, MD, Jeffrey A. Zonder, MD, Kevin Song, MD, Edward Stadtmauer, Alvin F. Wong, PharmD, Marcy Vallone, Yu-Lin Chang, Michael Kauffman, MD, PhD, Robert Z. Orlowski, MD, PhD, A. Keith Stewart, MBChB, Seema B. Singhal, MD, The MMRC
Journal: Blood
Blood (2010) 116 (21): 985.
https://doi.org/10.1182/blood.V116.21.985.985
Published: 2010
Journal Articles

Responses and Survival Are Not Affected by Cytogenetics In Patients with Relapsed and Refractory Multiple Myeloma (R/R MM) Treated with Single-Agent Carfilzomib

Andrzej J Jakubowiak, MD, PhD, Thomas Martin, MD, Seema B. Singhal, MD, Michael Wang, MD, Ravi Vij, MBBS, MD, Sundar Jagannath, MD, Sagar Lonial, MD, Vishal Kukreti, MD, FRCPC, Francis Buadi, MD, Lauren Bray, Marcy Vallone, Michael Kauffman, MD, PhD, Robert Z. Orlowski, MD, PhD, David Samuel diCapua Siegel, MD, PhD, The MMRC
Journal: Blood
Blood (2010) 116 (21): 1942.
https://doi.org/10.1182/blood.V116.21.1942.1942
Published: 2010
Journal Articles

Baseline Peripheral Neuropathy Does Not Impact the Efficacy and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ): Results of a Subset Analysis of a Phase 2 Trial In Patients with Relapsed and Refractory Multiple Myeloma (R/R MM)

Thomas Martin, MD, Seema B. Singhal, MD, Ravi Vij, MD, Michael Wang, MD, A. Keith Stewart, MBChB, Sundar Jagannath, MD, Sagar Lonial, MD, Andrzej J Jakubowiak, MD, PhD, Vishal Kukreti, MD, FRCPC, Nizar J Bahlis, MD, Melissa Alsina, MD, Asher A. Chanan-Khan, MD, George Somlo, MD, Francis Buadi, MD, Frederic J. Reu, MD, Jeffrey A. Zonder, MD, Kevin Song, MD, Edward A. Stadtmauer, MD, Alvin F. Wong, PharmD, Marcy Vallone, Yu-Lin Chang, Michael Kauffman, MD, PhD, Robert Z. Orlowski, MD, PhD, David Samuel diCapua Siegel, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 3031.
https://doi.org/10.1182/blood.V116.21.3031.3031
Published: 2010
Journal Articles

Influence of Cytogenetics in Patients with Relapsed and Refractory Multiple Myeloma (MM) Treated with Carfilzomib (CFZ).

Andrzej Jakubowiak, MD, PhD, Luhua Wang, MD, Robert Z Orlowski, M.D., Ph.D., Sundar Jagannath, MD, David Siegel, A. Keith Stewart, MD, Vishal Kukreti, MD, FRCPC, Sagar Lonial, MD, Kevin T. McDonagh, MD, Marcy Vallone, Michael Kauffman, MD, PhD, Ravi Vij, MD, The Multiple Myeloma Research Consortium (MMRC)
Journal: Blood
Blood (2009) 114 (22): 1827.
https://doi.org/10.1182/blood.V114.22.1827.1827
Published: 2009
Journal Articles

Safety and Antitumor Efficacy of the Proteasome Inhibitor Carfilzomib (PR-171) Dosed for Five Consecutive Days in Hematologic Malignancies: Phase 1 Results.

Robert Z. Orlowski, MD, PhD, Keith Stewart, MD, Marcy Vallone, Chris Molineaux, Lori Kunkel, MD, John Gericitano, MD, Owen A. O’Connor, MD
Journal: Blood
Blood (2007) 110 (11): 409.
https://doi.org/10.1182/blood.V110.11.409.409
Published: 2007
Journal Articles

Phase 1 Single Agent Antitumor Activity of Twice Weekly Consecutive Day Dosing of the Proteasome Inhibitor Carfilzomib (PR-171) in Hematologic Malignancies.

Melissa Alsina, MD, Suzanne Trudel, MD, Marcy Vallone, Christopher Molineaux, Lori Kunkel, MD, Andre Goy, MD
Journal: Blood
Blood (2007) 110 (11): 411.
https://doi.org/10.1182/blood.V110.11.411.411
Published: 2007